MALARIA VACCINE PRICE TO DROP BY 40% IN DEAL TO EXPAND ACCESS
Daily monitor
The Global Vaccine Alliance (Gavi) has announced an agreement to reduce the price of the RTS,S/AS01 malaria vaccine by approximately 40 per cent, in a move expected to expand access to the life-saving immunisation.
The deal, executed by UNICEF and financially backed by Gavi, is expected to generate about $50 million in savings between 2027 and 2029, according to a joint statement by the two organisations on Thursday.
The lower price, expected to take effect by early 2027, follows the transfer of vaccine production to a manufacturer in a developing country and reflects efforts to build a more sustainable and competitive malaria vaccine market, the agencies said.
“This agreement is an important step towards protecting more children from malaria by expanding access to life-saving vaccines where they are needed most,” Leila Pakkala, director of UNICEF’s Supply Division, said in the statement.
“At the same time, it sends a strong signal in support of continued innovation, helping to advance the development of next-generation vaccines that can further reduce the burden of malaria for future generations,” she added.
As demand for malaria vaccines grows, the agreement could help “protect up to one million more children” with the full four-dose course or enable countries to reach more children with other vaccines, Gavi and UNICEF said.
Enabled by an advance payment through the International Finance Facility for Immunisation (IFFIm), the deal will reduce the price to €5.50 per dose, approximately 40 per cent below the previous price, according to Gavi.
The agreement is subject to regulatory and manufacturing milestones, including World Health Organisation (WHO) prequalification of a new manufacturing facility expected to increase supply capacity. UNICEF will begin procuring doses under the arrangement once the requirements are met, Gavi said.
“Today’s announcement is a powerful example of what the Vaccine Alliance does best: bringing together financing, technical expertise and strategic partnerships to shape healthier vaccine markets and expand access for the children who need vaccines most,” An Vermeersch, Gavi’s chief vaccine programmes and markets officer, said.
According to Gavi, demand for malaria vaccines has exceeded initial forecasts since rollout began in 2024. More than 74 million doses have so far been procured and delivered by UNICEF.
The Gavi-funded malaria vaccination programme is now part of routine immunisation in 25 African countries that account for more than 70 per cent of the global malaria burden.
Gavi estimates that one child dies from malaria every minute, amounting to nearly half a million deaths annually. In 2024, there were an estimated 282 million malaria cases and 610,000 deaths globally, with Africa accounting for up to 95 per cent of both. About 74 per cent of malaria deaths were among children under five.
A full course of four vaccine doses reduces malaria cases by about 75 per cent when administered seasonally in areas with high seasonal transmission, Gavi said.
In Uganda, the Ministry of Health says the R21 malaria vaccine is used in the government’s free malaria immunisation programme, while the private sector has imported RTS,S/AS01.
Of the 25 countries that had introduced malaria vaccines at the time of the figures cited, 10 use RTS,S, 13 use R21, and two — Ghana and Burkina Faso — use both vaccines, according to the International Vaccine Access Center (IVAC). Both vaccines have been approved by the WHO.

Comments
This post currently has no comments.